ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference
April 18 2017 - 8:30AM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
applying a precision medicine approach to developing
genetically-targeted therapies for cardiovascular diseases, today
announced that it will present a corporate overview at the Planet
MicroCap Showcase 2017 Investor Conference, taking place April
26-28, 2017 in Las Vegas, Nevada.
Date: Thursday, April 27, 2017Time: 10:00 a.m.
(Pacific Daylight Time)Presenter: Thomas Keuer, Chief
Operating Officer
Webcast/Presentation: The live webcast and accompanying
slides will be available at http://wsw.com/webcast/planetmc/abio
and http://arcabio.com/investors/investor-presentations/,
respectively.
Replay Information: A replay of the webcast is expected
to be available approximately two hours after the presentation on
April 27, 2017, and will remain available for 90 days. The replay
can be accessed at http://wsw.com/webcast/planetmc/abio.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases through a precision medicine
approach to drug development. The Company's lead product candidate,
Gencaro™ (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common
genetic variations that it believes predict individual patient
response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA
has a collaboration with Medtronic, Inc. for support of the
GENETIC-AF trial. For more information, please visit
www.arcabio.com.
Safe Harbor Statement
This press release and the anticipated
presentation contain "forward-looking statements" for purposes of
the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. These statements include, but are not limited
to, statements regarding the potential that the data from 150
patients will support a recommendation that the GENETIC-AF trial
transition to Phase 3, the potential timeline for GENETIC-AF trial
activities and related recommendations of the DSMB, potential
timing for patient enrollment in the GENETIC-AF trial, the
sufficiency of the Company’s capital to support its operations, the
potential for genetic variations to predict individual patient
response to Gencaro, Gencaro’s potential to treat atrial
fibrillation, future treatment options for patients with atrial
fibrillation, and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management's current expectations and
involve risks and uncertainties. Actual results and performance
could differ materially from those projected in the forward-looking
statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: the
Company's financial resources and whether they will be sufficient
to meet the Company's business objectives and operational
requirements; results of earlier clinical trials may not be
confirmed in future trials, the protection and market exclusivity
provided by the Company’s intellectual property; risks related to
the drug discovery and the regulatory approval process; and, the
impact of competitive products and technological changes. These and
other factors are identified and described in more detail in ARCA’s
filings with the Securities and Exchange Commission, including
without limitation the Company’s annual report on Form 10-K for the
year ended December 31, 2016, and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170418005346/en/
Investor & Media Contact:ARCA biopharma,
Inc.Derek Cole, 720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024